Page 31 - Amgen News Today

Robert Rosenson, MD, discusses the unmet need in mixed hyperlipidemia and the potential for RNA interference therapies in this patient population.

Brendon Neuen, MBBS, PhD, joins the podcast to discuss the latest updates in nephrology, including the landmark FLOW trial.

Paradigm Asset Management Co. LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,300 shares of the medical research company’s stock after selling 200 shares […]

Connable Office Inc. lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 10,435 shares of the medical research company’s stock after selling 49 shares during the period. Connable Office Inc.’s holdings in Amgen were […]

The government's effort to treat childhood cancer has received a major boost with the donation of 1,510 vials of Amgen's rituximab worth...

Proquility Private Wealth Partners LLC lowered its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 19.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,895 shares of the medical research company’s stock after selling 711 shares during the quarter. Proquility Private Wealth Partners […]

Proquility Private Wealth Partners LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 19.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,895 shares of the medical research company’s stock after selling 711 shares […]

Palisades Hudson Asset Management L.P. decreased its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 40.0% during the 4th quarter, Holdings Channel reports. The fund owned 787 shares of the medical research company’s stock after selling 525 shares during the quarter. Palisades Hudson Asset Management L.P.’s holdings in Amgen were worth $227,000 as of […]

The growth of the binge eating disorder market is expected to be mainly driven by increasing prevalence, advancements in diagnosis, the launch of emerging therapies, and an upsurge in the geriatric

ETFs are very passive investments.